Breaking Down the Barriers: Can Lithium be the Answer for Future Antifungal Therapies?
By Alexandra Sébastien from the Foster Lab, Michael Smith Laboratories
Cryptococcus neoformans is a major human pathogenic fungus that is responsible for 15% of all AIDS-related deaths worldwide. It is particularly harmful to people with weakened immune systems as it can result in serious lung infections. In the most severe cases, C. neoformans can disseminate from the lungs to the brain, causing life-threatening meningitis. Dr. Francois Mayer, a postdoctoral fellow under Dr. Jim Kronstad’s supervision at the Michael Smith Laboratories, has investigated a promising new approach to target infections with C. neoformans.
Mayer’s expertise is in researching new ways to prevent or treat fungal infections in humans at the molecular and cellular level. He aims to identify new antifungal drug targets and agents that could be developed into antifungal therapies against infections with C. neoformans. In his latest paper published in Microbial Cell, Mayer builds off of his previous research on the importance of capsule production and biofilm formation for cryptococcal virulence. It was previously shown that C. neoformans mutants lacking genes coding for capsule-associated functions are strongly reduced in virulence. This result suggests that inhibiting capsule formation could be a potential approach in preventing or treating fungal infections. The Kronstad lab had previously discovered that lithium inhibits capsule formation by C. neoformans, however, mechanistic insight into the mode-of-action of lithium was still missing, spawning the inspiration for Mayer’s latest paper.
In his experiment, Mayer first identified pathways and proteins affected by lithium treatment by screening a large C. neoformans mutant collection. He found that a major effect of lithium was associated with the ubiquitin/proteasome system, the machinery involved in degrading and recycling proteins in the cell. Mayer then demonstrated that proteostasis is required for proper capsule and biofilm formation using mutants with defects in the ubiquitin/proteasome system. He proved a link between lithium activity and the proteasome system, prompting him to test a lithium-mimetic drug, ebselen, to see if it would block capsule and biofilm formation. This study was successful and indicated that the ubiquitin/proteasome system may be a promising new target for antifungal therapy.
“Because lithium is already an FDA-approved drug that is used at low concentrations to treat people with bipolar disorder, I wanted to investigate whether a clinically-relevant, low concentration of lithium would inhibit capsule formation by C. neoformans,” explains Mayer. “Encouragingly enough, this turned out to be the case.”
To further his research, Mayer plans to evaluate clinically relevant concentrations of lithium and combinations of lithium and proteasome inhibitors for antifungal efficacy in in vivo mouse infection models.